In a swift procedural development spanning just 43 days, the U.S. District Court for the Central District of California stayed Case No. 2:24-cv-04711 — Procter & Gamble’s patent infringement action against men’s personal care brand Dr. Squatch, LLC — pending the final resolution of inter partes review (IPR) proceedings, including any appeals thereof. Filed on June 5, 2024, and stayed by July 18, 2024, the action centers on five U.S. patents covering personal care product formulations, with eleven Dr. Squatch product lines — including Pine Tar, Bay Rum, and Wood Barrel Bourbon — named as accused products. The joint stipulation, granted by the court for good cause, signals that both parties agreed to pause district court proceedings while the USPTO adjudicates the validity of the asserted patents.

This case is a critical signal for IP strategists and R&D leaders in the personal care and consumer goods space. The simultaneous deployment of district court litigation and IPR challenges reflects a now-standard dual-track strategy that places enormous pressure on patent holders and accused infringers alike. Patent attorneys should monitor the pending IPRs closely, as their outcomes will directly determine whether P&G’s asserted claims survive and whether Dr. Squatch faces renewed infringement exposure — or gains freedom to operate across its growing product portfolio.

Case Overview

The Parties

The Patents at Issue

The five patents at issue — US10966915B2, US11540999B2, US10905647B2, US11497706B2, and US11844752B2 — collectively cover formulations and technologies related to personal care products, likely encompassing compositions for bar soaps, cleansing agents, and skin-conditioning delivery systems used in men’s grooming. These patents protect specific ingredient combinations, structural formulations, or application methods that differentiate consumer personal care products in terms of performance, skin feel, or sensory experience. Their real-world application spans the development of premium bar soaps and body care items of the type commercialized by both P&G and Dr. Squatch in the competitive men’s grooming market.

• • US10966915B2
• • US11540999B2
• • US10905647B2
• • US11497706B2
• • US11844752B2

Legal Representation

Plaintiff Counsel: Jones Day (lead: Andrea Weiss Jeffries)
Defendant Counsel: Venable LLP (lead: Joshua D. Calabro)

Litigation Timeline & Procedural History

This case was filed in the U.S. District Court for the Central District of California — one of the busiest and most plaintiff-favorable federal venues for consumer products IP litigation. As a first-instance district court action, this case represented the opening salvo in what could become a multi-year, multi-forum dispute between two significant players in the men’s personal care market, with the district court serving as the primary venue for adjudicating infringement while the USPTO’s Patent Trial and Appeal Board (PTAB) handles validity challenges through the IPR process.

At just 43 days from filing to stay — June 5 to July 18, 2024 — this case reached a procedural pause at an exceptionally rapid pace, reflecting a pre-negotiated agreement between the parties rather than any substantive judicial ruling on the merits. The basis of termination was a court-granted stay pursuant to a Joint Stipulation, meaning both Procter & Gamble and Dr. Squatch mutually agreed to suspend district court proceedings pending the final resolution of inter partes review proceedings, including all appeals. This dual-track strategy — filing infringement claims while simultaneously pursuing IPRs — is increasingly common in high-stakes patent disputes and effectively transfers the threshold patent validity question to the PTAB before any infringement determination is made at the district court level.

The Verdict & Legal Analysis

Outcome

The Central District of California granted the parties’ Joint Stipulation to Stay on July 18, 2024, halting all district court proceedings in Case No. 2:24-cv-04711 pending final resolution of the inter partes reviews covering the five asserted patents, including any appellate proceedings before the Federal Circuit. No damages were awarded, no injunctive relief was issued, and no merits determination was reached — the court explicitly acted in the interest of judicial economy. The case remains stayed and will resume only upon final resolution of all pending IPR proceedings.

Verdict Cause Analysis

The court’s grant of the stay reflects several well-established legal and procedural principles governing the intersection of district court patent litigation and PTAB validity proceedings.

• Both parties jointly stipulated to the stay, eliminating any adversarial opposition and enabling the court to grant the motion on good cause without a full briefing cycle — a hallmark of cases where IPR institution has already been granted or is strategically anticipated.
• Courts in the Central District of California routinely weigh three factors when considering litigation stays pending IPR: simplification of issues, stage of litigation, and potential prejudice to the non-moving party — all of which favored a stay given the early filing date and bilateral agreement.
• The stay applies pending ‘final resolution of each of the pending IPRs, including appeal thereof,’ meaning the district court action could remain dormant for several years if PTAB decisions are appealed to the Federal Circuit.
• With five patents and eleven accused product lines at issue, the scope of potential IPR outcomes is substantial — if even one patent is invalidated at the PTAB, it could materially narrow P&G’s infringement claims upon return to district court.

Legal Significance

1. This case reinforces the strategic utility of the dual-track approach — filing district court infringement actions in parallel with or shortly after IPR petitions — as a mechanism to pressure defendants while preserving the option to pause costly district court discovery pending PTAB review.
2. The joint stipulation stay structure, as opposed to a contested stay motion, signals that Dr. Squatch may have filed or supported IPR petitions challenging the five asserted patents, and that both parties recognized a PTAB ruling on validity would be dispositive of the scope of any eventual infringement trial.
3. For practitioners, this case illustrates that early-stage stays pending IPR are increasingly obtainable in the Central District of California when both parties consent, setting a practical precedent for structuring patent disputes involving multiple patents and broad accused product lines in the consumer goods sector.

Strategic Takeaways

For Patent Attorneys:

• When representing defendants facing multi-patent infringement actions in consumer goods, consider filing IPR petitions promptly to create leverage for a joint stay stipulation, potentially halting costly district court litigation before significant discovery expenses are incurred.
• Draft IPR petitions with appellate endurance in mind — given that this stay extends ‘including appeal thereof,’ the timeline to district court resumption could exceed three to four years, and patent claims should be challenged on grounds most likely to survive Federal Circuit scrutiny.
• For plaintiffs like P&G asserting multiple patents against a single defendant, a portfolio-wide IPR exposure analysis before filing suit is essential to avoid a scenario where a stay benefits the defendant by delaying injunctive relief while IPRs erode the asserted claim set.

For IP Professionals:

• In-house IP teams at consumer brands should monitor the PTAB dockets for IPR petitions filed against P&G’s US10966915B2, US11540999B2, US10905647B2, US11497706B2, and US11844752B2, as any institution decisions or final written decisions will signal the future trajectory of this litigation and affect freedom-to-operate assessments across the men’s grooming sector.
• Companies in the personal care space with products similar to Dr. Squatch’s accused lines — including natural-ingredient soaps, botanical cleansers, and men’s body care items — should conduct proactive patent clearance reviews against P&G’s personal care formulation portfolio to identify exposure before receiving a demand letter or complaint.

For R&D Teams:

• R&D teams developing men’s grooming or bar soap formulations should treat the five asserted P&G patents as active FTO risks and work with patent counsel to identify claim limitations that may permit design-around formulations — particularly if the IPRs result in narrowed but surviving claims.
• The eleven accused Dr. Squatch product lines, spanning scent profiles from Pine Tar to Rainforest Rapids, suggest that P&G’s patent claims may cover broad formulation categories rather than a single product type, meaning new product development in the natural soap and men’s body care segment should be reviewed against these patents prior to commercial launch.